Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431561
Status:
COMPLETED
Last Update Posted:
2013-12-03
First Post:
2007-02-05
Brief Title:
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Sponsor:
Isarna Therapeutics GmbH
Organization:
Isarna Therapeutics GmbH
Organization Data
Organization:
Isarna Therapeutics GmbH
Class:
INDUSTRY
Study ID:
AP 12009-G004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Isarna Therapeutics GmbH
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Hubert Heinrichs MD PhD Chief Medical Officer
Old Organization:
Antisense Pharma